查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1715471

帕金森氏症藥物市場按藥物類別、給藥途徑、劑型、目標區域和分銷管道分類－2025-2030 年全球預測

Parkinson's Disease Therapeutics Market by Drug Class, Route Of Administration, Drug Form, Targeted Area, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

帕金森氏症藥物市場預計到 2024 年將達到 58.1 億美元，2025 年將達到 61.4 億美元，到 2030 年將達到 82.1 億美元，複合年成長率為 5.93%。

主要市場統計數據
基準年2024年 58.1億美元
預計2025年 61.4億美元
預測年份 2030 82.1億美元
複合年成長率（%） 5.93%

帕金森氏症是最具挑戰性的神經退化性疾病之一，需要不斷創新治療方法。近年來，研究和臨床試驗取得了漸進式和突破性的進展，不僅解決了這種複雜疾病的運動症狀，而且解決了非運動方面的問題。治療方法的進步正在開啟一個新時代，精準醫療和個人化治療計畫將越來越成為病患照護不可或缺的一部分。透過更了解疾病途徑、改進診斷技術和旨在減少副作用和改善患者預後的新型藥物傳遞方法，目前的治療模式得到了增強。

本介紹為深入討論影響帕金森氏症藥物的多方面動態奠定了基礎。值得注意的是，臨床醫生、研究人員和行業專家之間的持續合作對於確定未來的治療策略至關重要。透過形成全面的觀點，相關人員可以更好地預測監管要求、報銷模式和患者期望的變化。科學技術的融合正在重新定義治療流程，並為患者和看護者帶來希望。本摘要概述了變革性轉變、細分洞察、全球區域動態、有影響力的市場參與者以及有助於在這個不斷發展的領域進行策略決策的可行建議，為您進入後續章節提供了必要的背景資訊。

改變帕金森氏症藥物市場

近年來，帕金森氏症的治療發生了變革性的變化，重塑了舊的治療模式並引入了創新的治療方法。這種轉變是由突破性的研究帶來的，它重新定義了我們思考和提供治療性介入的方式。神經藥理學的進步現在可以更有針對性地調節多巴胺能系統，新技術正在提高藥物傳遞的精確度。推動這股勢頭的是臨床試驗設計的改進，更重視長期療效和安全性。

同時，對疾病異質性的深入了解也迫使臨床醫師重新思考其一刀切的治療方法。該行業目前專注於考慮到患者獨特的基因和症狀特徵的個人化治療方法。這種個人化不僅最佳化了臨床結果，而且還有助於減少與傳統治療方法相關的副作用。此外，數位健康解決方案和遠端患者監護對於管理疾病進展變得至關重要，使臨床醫生能夠近乎即時地調整治療策略。學術機構和生物技術公司之間的合作正在迅速縮小實驗室發現和臨床應用之間的差距，為帕金森氏症藥物前所未有的成長和創新時代奠定了基礎。

按市場區隔的關鍵見解

帕金森氏症治療領域的市場細分為了解治療策略如何多樣化以滿足特定患者的需求提供了重要的見解。依藥物類別細分研究治療方案，例如抗膽鹼能藥物、碳度巴-左旋多巴、COMT 抑制劑、多巴胺促效劑和 MAO-B 抑制劑。這種分類有助於細緻地了解不同類別如何發揮不同的治療效果以及如何針對特定患者情況進行最佳化。

此外，按給藥途徑細分突顯了腸內注射、口服技術、皮下注射和局部應用在實現理想藥物動力學特徵方面所扮演的重要角色。依藥物形式進一步細分，可揭示注射劑、錠劑、膠囊、經皮吸收貼片劑型對患者依從性和療效的影響。此外，非典型帕金森氏症、藥物性帕金森氏症、遺傳性帕金森氏症、特發性帕金森氏症和血管性帕金森氏症相關治療的主題區域細分突顯了疾病的不同表現如何需要不同的治療途徑。最後，對分銷管道的細分，評估醫院藥房、線上藥房和零售藥房，說明了不斷變化的消費行為和醫療保健服務模式的適應性，以確保更廣泛的覆蓋範圍。

這種詳細的細分凸顯了該行業提高精準度、更有效地客製化治療方法以及最終改善患者照護整體軌蹟的動力。

目錄

第1章 引言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章 市場洞察

  • 市場動態
    • 驅動程式
      • 隨著全球老齡人口的增加，帕金森氏症的發生率也增加
      • 透過生物標記識別和基因監測實現個人化醫療方法的出現
      • 增強醫療保健基礎設施並改善專科神經病學中心的可及性
    • 限制因素
      • 副作用風險高，降低病患依從性和整體接受度
    • 機會
      • 整合人工智慧演算法和巨量資料分析，最佳化個人化治療的預測模型
      • 增加對早期診斷檢測和先進成像技術的投資將有助於及時發現
    • 任務
      • 不同地區的法規結構複雜且合規標準嚴格
  • 市場區隔分析
    • 藥物類別：Lovopoda 類藥物越來越受到青睞，可以增加進入大腦的左旋多巴的量
    • 重點領域：闡明藥物對藥物性帕金森氏症引起的神經系統影響
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社會
    • 技術的
    • 合法的
    • 環境

6. 帕金森氏症藥物市場（依藥物類別）

  • 抗膽鹼藥物
  • Carbidopa-Levodopa
  • COMT抑制劑
  • 促效劑
  • MAO-B抑制劑

7. 帕金森氏症藥物市場（依給藥途徑）

  • 腸道注射
  • 口服
  • 皮下
  • 話題

第 8 章：帕金森氏症藥物市場（以藥物劑型）

  • 注射
  • 錠劑和膠囊
  • 經皮吸收貼片

第9章帕金森氏症藥物市場（按目標區域）

  • 非典型帕金森氏症
  • 藥物引起的帕金森氏症
  • 遺傳性帕金森氏症
  • 特發性帕金森氏症
  • 血管性帕金森氏症

第 10 章帕金森氏症藥物市場（按分銷管道）

  • 醫院藥房
  • 網路藥局
  • 零售藥局

第 11 章：美洲帕金森氏症藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

12. 亞太帕金森氏症藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

13. 歐洲、中東和非洲帕金森氏症藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2024年市場佔有率分析
  • 2024年FPNV定位矩陣
  • 競爭情境分析
  • 戰略分析與建議

公司名單

  • Apotex Inc.
  • Aurobindo Pharma Limited
  • Biogen Inc
  • Bristol-Myers Squibb Company
  • Cadila Healthcare Limited
  • Cipla Limited
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Glenmark Pharmaceuticals Ltd.
  • H. Lundbeck A/S
  • Hikma Pharmaceuticals PLC
  • Lupin Limited
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Sumitomo Dainippon Pharma Co., Ltd.
  • Teva Pharmaceutical Industries Limited
  • TORRENT PHARMACEUTICALS LTD
  • UCB SA
Product Code: MRR-036C5CF3B54D

The Parkinson's Disease Therapeutics Market was valued at USD 5.81 billion in 2024 and is projected to grow to USD 6.14 billion in 2025, with a CAGR of 5.93%, reaching USD 8.21 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 5.81 billion
Estimated Year [2025] USD 6.14 billion
Forecast Year [2030] USD 8.21 billion
CAGR (%) 5.93%

Parkinson's disease continues to stand as one of the most challenging neurodegenerative conditions, demanding continuous innovation in therapeutic approaches. In recent years, research and clinical trials have led to both incremental and revolutionary advancements that not only address the motor symptoms but also the non-motor aspects of this complex condition. The evolving landscape of therapeutics has ushered a new era where precision medicine and personalized treatment plans are increasingly becoming integral to patient care. Current treatment paradigms are being reinforced by a deeper understanding of disease pathways, improved diagnostic techniques, and novel drug delivery methods that aim to reduce side effects and enhance patient outcomes.

This introduction sets the stage for a robust discussion on the multifaceted dynamics influencing Parkinson's disease therapeutics. It is important to note that continuous collaboration between clinicians, researchers, and industry experts is critical in defining the future course of therapy. By fostering a comprehensive perspective, stakeholders can better anticipate shifts in regulatory requirements, reimbursement models, and patient expectations. The convergence of science and technology is redefining treatment algorithms, offering hope to patients and caregivers alike. As we delve into the subsequent sections, this summary provides the necessary context by outlining the transformative shifts, segmentation insights, global regional dynamics, influential market players, and actionable recommendations that will inform strategic decisions in this evolving field.

Transformative Shifts in the Therapeutic Landscape

Recent years have brought transformative shifts in the therapeutic landscape of Parkinson's disease, reshaping old paradigms and introducing innovative treatment modalities. These shifts are driven by groundbreaking research that has redefined how therapeutic interventions are conceived and administered. Advances in neuropharmacology now enable more targeted modulation of the dopaminergic system, while emerging technologies offer improved precision in drug delivery. Driving this momentum are improved clinical trial designs, which have increasingly focused on long-term efficacy and safety, ensuring that novel therapies are both sustainable and accessible to a broader patient base.

Concurrently, an enhanced understanding of disease heterogeneity has forced practitioners to reconsider one-size-fits-all approaches. The industry is now emphasizing individualized treatment regimens that account for a patient's unique genetic and symptomatic profile. This personalization not only optimizes clinical outcomes but also helps in mitigating adverse effects associated with traditional therapies. Additionally, digital health solutions and remote patient monitoring are becoming integral in managing disease progression, enabling clinicians to adjust therapeutic strategies in near real time. Collaborative research across academic institutions and biotech companies is rapidly bridging the gap between laboratory discoveries and bedside applications, setting the stage for a period of unprecedented growth and innovation in Parkinson's therapeutics.

Key Insights from Market Segmentation

Market segmentation in the field of Parkinson's disease therapeutics provides critical insight into the myriad ways in which treatment strategies are being diversified to meet specific patient needs. The segmentation based on drug class involves a spectrum of treatment options studying anticholinergics, Carbidopa-Levodopa, COMT inhibitors, dopamine agonists, and MAO-B inhibitors. This classification facilitates a nuanced understanding of how different classes exert distinct therapeutic benefits and how they can be optimized for specific patient profiles.

Moreover, segmentation by route of administration highlights the significant roles played by intestinal infusion, oral methodologies, subcutaneous injections, and topical applications in achieving desired pharmacokinetic profiles. A further split based on drug form elucidates the impact of formulations such as injections, tablets and capsules, as well as transdermal patches on patient compliance and efficacy. Additionally, a targeted area segmentation sheds light on treatments associated with atypical Parkinsonian conditions, drug-induced Parkinsonism, genetic Parkinson's, idiopathic Parkinson's, and vascular Parkinsonism, emphasizing how variant presentations of the disease necessitate different therapeutic pathways. Lastly, the distribution channel segmentation, which evaluates hospital pharmacy, online pharmacy, and retail pharmacy outlets, is indicative of evolving consumer behaviors and adapting healthcare delivery models that ensure wider accessibility.

This detailed segmentation underscores the industry's drive to harness precision, tailor therapies more effectively, and ultimately improve the overall trajectory of patient care.

Based on Drug Class, market is studied across Anticholinergics, Carbidopa-Levodopa, COMT inhibitors, Dopamine Agonists, and MAO-B Inhibitors.

Based on Route Of Administration, market is studied across Intestinal Infusion, Oral, Subcutaneous, and Topical.

Based on Drug Form, market is studied across Injections, Tablets & Capsules, and Transdermal Patches.

Based on Targeted Area, market is studied across Atypical Parkinsonian, Drug-Induced Parkinsonism, Genetic Parkinson's, Idiopathic Parkinson's, and Vascular Parkinsonism.

Based on Distribution Channel, market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.

Regional Dynamics Influencing Therapeutic Adoption

An analysis of the regional landscape uncovers significant variations in how Parkinson's disease therapeutics are adopted and integrated across different markets. The Americas have demonstrated a robust infrastructure backed by substantial investments in advanced research and state-of-the-art clinical practices. Meanwhile, regions encompassing Europe, the Middle East, and Africa are marked by proactive regulatory frameworks and a surge in collaborative alliances between governments and pharmaceutical innovators, thereby fostering an environment conducive to breakthrough therapies. In the Asia-Pacific region, rapid economic growth combined with increasing healthcare expenditure and a rising incidence of Parkinson's disease has driven remarkable advancements in treatment modalities and delivery systems.

These regional insights illustrate that while challenges remain in standardizing care across diverse healthcare settings, the evolving global landscape offers unique opportunities to harmonize research efforts and address patient needs more effectively. The interplay between regulatory reforms, funding allocations, and cultural nuances in each region further shapes the adoption curve and paves the way for strategic market entry and expansion.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Influential Companies Shaping the Market

Key market players are at the forefront of revolutionizing Parkinson's disease therapeutics, driving innovation and operational excellence in the sector. Industry leaders such as Apotex Inc. and Aurobindo Pharma Limited have consistently pushed the boundaries in generic formulation development, while companies like Biogen Inc. and Bristol-Myers Squibb Company leverage extensive research pipelines to deliver precision therapies. Cadila Healthcare Limited and Cipla Limited continue to strengthen their market presence through affordable yet effective treatment solutions.

Global pharmaceutical titans including Eisai Co., Ltd., Eli Lilly and Company, and GlaxoSmithKline plc have contributed significantly to the development of advanced drug formulations that emphasize both efficacy and patient convenience. In parallel, organizations such as Glenmark Pharmaceuticals Ltd., H. Lundbeck A/S, and Hikma Pharmaceuticals PLC are pivotal in initiating clinical studies that explore novel therapeutic mechanisms. Other influential companies like Lupin Limited, Merck & Co., Inc., Mitsubishi Tanabe Pharma Corporation, and Novartis AG have been instrumental in adapting to rapid market shifts through strategic investments in research and development. Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., Sumitomo Dainippon Pharma Co., Ltd., Teva Pharmaceutical Industries Limited, TORRENT PHARMACEUTICALS LTD, and UCB S.A. are equally contributing to this dynamic scenario by pushing forward innovative treatments that cater to diverse patient demographics.

Together, these companies form an ecosystem that not only drives clinical advancements but also fosters a competitive environment where continual improvement becomes the norm, ensuring that patients benefit from the most updated and effective treatment strategies available.

The report delves into recent significant developments in the Parkinson's Disease Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Apotex Inc., Aurobindo Pharma Limited, Biogen Inc, Bristol-Myers Squibb Company, Cadila Healthcare Limited, Cipla Limited, Eisai Co., Ltd., Eli Lilly and Company, GlaxoSmithKline plc, Glenmark Pharmaceuticals Ltd., H. Lundbeck A/S, Hikma Pharmaceuticals PLC, Lupin Limited, Merck & Co., Inc., Mitsubishi Tanabe Pharma Corporation, Novartis AG, Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., Sumitomo Dainippon Pharma Co., Ltd., Teva Pharmaceutical Industries Limited, TORRENT PHARMACEUTICALS LTD, and UCB S.A.. Actionable Recommendations for Industry Leaders

For stakeholders within Parkinson's disease therapeutics, strategic planning and investment are crucial in navigating this evolving market. Industry leaders are advised to concentrate on the development of therapies that not only address motor symptoms but also work to mitigate non-motor manifestations, thus offering holistic patient care. Identifying and capitalizing on emerging trends in precision medicine and targeted drug delivery will serve as key differentiators in an increasingly competitive arena. It is essential to invest in advanced research collaborations and clinical trials that explore multi-faceted treatment options, thereby reducing time-to-market for innovative drug solutions.

Fostering partnerships with academic institutions, biotech firms, and healthcare providers can greatly enhance the ability to personalize treatments for varied patient profiles. Leaders are encouraged to bolster digital platforms that support telemedicine and remote patient monitoring, enabling more efficient and timely adjustments in therapy regimens. Additionally, an emphasis on regulatory compliance, market authorization processes, and strategic communication with policymakers is critical to ensure seamless market entry and sustained growth. By streamlining operations and leveraging cutting-edge technological solutions, decision-makers can enhance patient engagement, optimize supply chain logistics, and ultimately secure a competitive advantage in a rapidly transforming market.

In summary, a forward-thinking approach that embraces innovation, collaboration, and adaptability will be key to transforming challenges into opportunities, ensuring long-term success in the therapeutic landscape.

Conclusion: Navigating the Evolving Therapeutic Sphere

The continuous evolution in Parkinson's disease therapeutics is a testament to the remarkable strides achieved by industry experts, researchers, and clinicians alike. As the treatment landscape expands, a multi-pronged approach that involves advanced drug formulations, innovative delivery systems, and personalized care models becomes indispensable. Reflection on the recent transformative shifts, detailed segmentation insights, profound regional dynamics, and influential market players reveals a sector in vigorous transformation.

The synthesis of robust clinical data, technological innovations, and strategic market insights underscores the potential for enhanced patient outcomes and improved quality of life. While challenges remain, the collaborative efforts across scientific, regulatory, and commercial domains represent a driving force that is reshaping the future of neurodegenerative disease management. With a commitment to continuous improvement and adaptive strategies, the industry is well-positioned to tackle the complexities inherent in Parkinson's disease, paving the way for more effective and patient-centric therapies.

Ultimately, this journey is not only about overcoming the limitations of current treatment paradigms but also about laying a solid foundation for tomorrow's breakthroughs. The integration of diverse insights and actionable strategies will continue to steer the industry toward a future where innovation serves as the cornerstone for better health outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing elderly population with rising incidence rates of Parkinson's disease globally
      • 5.1.1.2. Emergence of personalized medicine approaches through biomarker identification and genetic research
      • 5.1.1.3. Enhanced healthcare infrastructure and improved access to specialized neurology centers
    • 5.1.2. Restraints
      • 5.1.2.1. High risk of adverse side effects reducing patient adherence and overall acceptance
    • 5.1.3. Opportunities
      • 5.1.3.1. Integration of AI algorithms and big data analytics to optimize predictive models for individualized treatment
      • 5.1.3.2. Rising investments in early diagnostic testing and advanced imaging techniques to facilitate timely detection
    • 5.1.4. Challenges
      • 5.1.4.1. Complex regulatory frameworks and meeting rigorous compliance standards across different region
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Drug Class: Growing preference for Lovopoda drug class to enhances the amount of levodopa entering the brain
    • 5.2.2. Targeted Area: Unraveling the neurological effects triggered by medication in drug-induced parkinsonism
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Parkinson's Disease Therapeutics Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Anticholinergics
  • 6.3. Carbidopa-Levodopa
  • 6.4. COMT inhibitors
  • 6.5. Dopamine Agonists
  • 6.6. MAO-B Inhibitors

7. Parkinson's Disease Therapeutics Market, by Route Of Administration

  • 7.1. Introduction
  • 7.2. Intestinal Infusion
  • 7.3. Oral
  • 7.4. Subcutaneous
  • 7.5. Topical

8. Parkinson's Disease Therapeutics Market, by Drug Form

  • 8.1. Introduction
  • 8.2. Injections
  • 8.3. Tablets & Capsules
  • 8.4. Transdermal Patches

9. Parkinson's Disease Therapeutics Market, by Targeted Area

  • 9.1. Introduction
  • 9.2. Atypical Parkinsonian
  • 9.3. Drug-Induced Parkinsonism
  • 9.4. Genetic Parkinson's
  • 9.5. Idiopathic Parkinson's
  • 9.6. Vascular Parkinsonism

10. Parkinson's Disease Therapeutics Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Hospital Pharmacy
  • 10.3. Online Pharmacy
  • 10.4. Retail Pharmacy

11. Americas Parkinson's Disease Therapeutics Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Parkinson's Disease Therapeutics Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Parkinson's Disease Therapeutics Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2024
  • 14.2. FPNV Positioning Matrix, 2024
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Mitsubishi Tanabe Pharma America unveils three-tear data for ND0612 in parkinson's disease
    • 14.3.2. Vesalius and GSK forge alliance to Parkinson's treatment
    • 14.3.3. New immunoassay platform enhances parkinson's disease research
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Apotex Inc.
  • 2. Aurobindo Pharma Limited
  • 3. Biogen Inc
  • 4. Bristol-Myers Squibb Company
  • 5. Cadila Healthcare Limited
  • 6. Cipla Limited
  • 7. Eisai Co., Ltd.
  • 8. Eli Lilly and Company
  • 9. GlaxoSmithKline plc
  • 10. Glenmark Pharmaceuticals Ltd.
  • 11. H. Lundbeck A/S
  • 12. Hikma Pharmaceuticals PLC
  • 13. Lupin Limited
  • 14. Merck & Co., Inc.
  • 15. Mitsubishi Tanabe Pharma Corporation
  • 16. Novartis AG
  • 17. Otsuka Pharmaceutical Co., Ltd.
  • 18. Pfizer Inc.
  • 19. Sumitomo Dainippon Pharma Co., Ltd.
  • 20. Teva Pharmaceutical Industries Limited
  • 21. TORRENT PHARMACEUTICALS LTD
  • 22. UCB S.A.

LIST OF FIGURES

  • FIGURE 1. PARKINSON'S DISEASE THERAPEUTICS MARKET MULTI-CURRENCY
  • FIGURE 2. PARKINSON'S DISEASE THERAPEUTICS MARKET MULTI-LANGUAGE
  • FIGURE 3. PARKINSON'S DISEASE THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 4. PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
  • FIGURE 17. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 19. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 21. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 23. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 25. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 26. PARKINSON'S DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 27. PARKINSON'S DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. PARKINSON'S DISEASE THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. PARKINSON'S DISEASE THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY CARBIDOPA-LEVODOPA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DOPAMINE AGONISTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY MAO-B INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY INTESTINAL INFUSION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY INJECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TABLETS & CAPSULES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TRANSDERMAL PATCHES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ATYPICAL PARKINSONIAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG-INDUCED PARKINSONISM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GENETIC PARKINSON'S, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY IDIOPATHIC PARKINSON'S, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY VASCULAR PARKINSONISM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 47. BRAZIL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 51. CANADA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 52. CANADA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 55. MEXICO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 56. MEXICO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 57. MEXICO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 61. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 62. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 63. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 70. AUSTRALIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 71. AUSTRALIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 72. AUSTRALIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 73. AUSTRALIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 74. AUSTRALIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 75. CHINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 76. CHINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 77. CHINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 78. CHINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 79. CHINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 80. INDIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 81. INDIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 82. INDIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 83. INDIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 84. INDIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 85. INDONESIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 86. INDONESIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 87. INDONESIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 88. INDONESIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 89. INDONESIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 90. JAPAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 91. JAPAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 92. JAPAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 93. JAPAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 94. JAPAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 95. MALAYSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 96. MALAYSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 97. MALAYSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 98. MALAYSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 99. MALAYSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 100. PHILIPPINES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 101. PHILIPPINES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 102. PHILIPPINES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 103. PHILIPPINES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 104. PHILIPPINES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 105. SINGAPORE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 106. SINGAPORE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 107. SINGAPORE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 108. SINGAPORE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 109. SINGAPORE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 110. SOUTH KOREA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 111. SOUTH KOREA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 112. SOUTH KOREA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 113. SOUTH KOREA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 114. SOUTH KOREA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 115. TAIWAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 116. TAIWAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 117. TAIWAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 118. TAIWAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 119. TAIWAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 120. THAILAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 121. THAILAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 122. THAILAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 123. THAILAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 124. THAILAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 125. VIETNAM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 126. VIETNAM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 127. VIETNAM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 128. VIETNAM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 129. VIETNAM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 136. DENMARK PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 137. DENMARK PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 138. DENMARK PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 139. DENMARK PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 140. DENMARK PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 141. EGYPT PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 142. EGYPT PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 143. EGYPT PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 144. EGYPT PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 145. EGYPT PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 146. FINLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 147. FINLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 148. FINLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 149. FINLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 150. FINLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 151. FRANCE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 152. FRANCE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 153. FRANCE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 154. FRANCE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 155. FRANCE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 156. GERMANY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 157. GERMANY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 158. GERMANY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 159. GERMANY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 160. GERMANY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 161. ISRAEL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 162. ISRAEL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 163. ISRAEL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 164. ISRAEL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 165. ISRAEL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 166. ITALY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 167. ITALY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 168. ITALY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 169. ITALY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 170. ITALY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 171. NETHERLANDS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 172. NETHERLANDS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 173. NETHERLANDS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 174. NETHERLANDS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 175. NETHERLANDS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 176. NIGERIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 177. NIGERIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 178. NIGERIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 179. NIGERIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 180. NIGERIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 181. NORWAY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 182. NORWAY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 183. NORWAY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 184. NORWAY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 185. NORWAY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 186. POLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 187. POLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 188. POLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 189. POLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 190. POLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 191. QATAR PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 192. QATAR PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 193. QATAR PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 194. QATAR PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 195. QATAR PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 196. RUSSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 197. RUSSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 198. RUSSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 199. RUSSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 200. RUSSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 201. SAUDI ARABIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 202. SAUDI ARABIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 203. SAUDI ARABIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 204. SAUDI ARABIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 205. SAUDI ARABIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 208. SOUTH AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 209. SOUTH AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 210. SOUTH AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 211. SPAIN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 212. SPAIN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 213. SPAIN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 214. SPAIN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 215. SPAIN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 216. SWEDEN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 217. SWEDEN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 218. SWEDEN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 219. SWEDEN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 220. SWEDEN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 221. SWITZERLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 222. SWITZERLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 223. SWITZERLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 224. SWITZERLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 225. SWITZERLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 226. TURKEY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 227. TURKEY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 228. TURKEY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 229. TURKEY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 230. TURKEY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED ARAB EMIRATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED ARAB EMIRATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED ARAB EMIRATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED ARAB EMIRATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED ARAB EMIRATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED KINGDOM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED KINGDOM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 238. UNITED KINGDOM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 239. UNITED KINGDOM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 240. UNITED KINGDOM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 241. PARKINSON'S DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • TABLE 242. PARKINSON'S DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024